Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Asthma (16)
  • Biologicals (5)
  • Biomarkers (3)
  • COVID19 (1)
  • Environmental allergy and climate change (1)
  • Immune deficiencies and autoimmunity (2)
  • Infections (3)
  • x Mastocytosis and mast cells (1)
  • Microbiome (1)
  • Occupational allergy (2)
  • Pediatrics (10)
Poster available until
Poster categories
keywords
Session Reference
  • L-TPS08 (1)
  • L-TPS10 (1)
  • L-TPS11 (1)
  • L-TPS13 (1)
  • L-TPS18 (2)
  • L-TPS20 (1)
  • L-TPS21 (1)
  • TPS02 (1)
  • TPS05 (1)
  • TPS09 (2)
  • TPS11 (1)
  • TPS13 (1)
  • TPS15 (2)
  • TPS16 (1)
  • TPS17 (1)
  • TPS37 (3)
  • TPS41 (1)
  • TPS43 (2)
  • TPS49 (1)
  • TPS55 (5)
  • x TPS56 (1)
  • TPS57 (2)
  • TPS67 (3)
  • TPS68 (1)
  • TPS71 (11)
1 results
Thumbnail

- D3.117 - Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117) Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 Mice

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM